Stock Analysis of Qualigen Therapeutics Inc (QLGN) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code QLGN
Close 0.293
Change -0.0055 / 1.84 %
Volume 149254
Vol Change -163959.00 / 52.35 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index Very Low Growth Stock
Value Index No Significant Value
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Qualigen Therapeutics Inc
PE (TTM)

-0.083

Very Poor
Price / Book

0.438

Excellent
Price / Sales

0.137

Excellent
Piotroski F Score

3.0

Not Good
Market Cap

1848.06 K

Enterprise Value

2745.47 K

ROA (TTM)

-156.96

Very Poor
ROE (TTM)

-709.27

Very Poor
Net Margin (TTM)

-165.16

Very Poor
Revenue

0 %

4983.56 K
Net Profit

17.57 %

-17339.21 K
Debt to Equity

-0.618

Very Poor
Altman Z Score

-107.01

Very Poor
Quick Ratio

0

Poor
Cash Ratio

0.097

Poor


Highs/Lows of Qualigen Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.2845 2.99 % 1.54 % 0.310.2616-May-2414-May-24
Two Week0.301 2.66 % 3.42 % 0.320.2606-May-2414-May-24
One Month0.2974 1.48 % 5.60 % 0.3340.2603-May-2414-May-24
Three Month0.4743 38.22 % 5.95 % 0.58530.2626-Feb-2414-May-24
Six Months0.72 59.31 % 17.48 % 0.78260.2629-Nov-2314-May-24
One year0.9601 69.48 % 27.52 % 1.250.2601-Aug-2314-May-24
Two year5.217 94.38 % 29.70 % 3.240.2604-Oct-2214-May-24
Five year205.0 99.86 % 85.46 % 4.290.2618-Aug-2213-May-24


Technical View of Qualigen Therapeutics Inc
RSI

43.76

Neutral
MACD

-0.0153

Bullish
ADX

12.01

Mild Bearish
Super Trend

0.364

Mild Bearish
Williams %R

-55.41

Neutral
CCI

-17.87

Neutral


EMA 5

0.294

Strong Bearish
EMA 15

0.296

Neutral
EMA 50

0.346

Mild Bearish
EMA 100

0.436

Mild Bearish
SMA 100

0.422

Mild Bearish
SMA 200

0.651

Strong Bearish
SMA 5 / 20

0.292 / 0.294

Mild Bearish
SMA 15 / 50

0.291 / 0.342

Mild Bearish
SMA 50 / 200

0.342 / 0.651

Strong Bearish




Charts of Qualigen Therapeutics Inc


Returns of Qualigen Therapeutics Inc with Peers
Period / StockQLGNMTPDRMAPXMD
1 Week2.99%-5.89%1070.89%15.99%
1 Mth-1.48%-81.95%1324.21%-69.98%
3 Mth-38.22%-89.62%813.04%-63.57%
6mth-59.31%-96.39%500.00%-86.28%
1 Year-69.48%-98.56%56.13%-99.06%
2 Year-94.38%-99.33%-61.96%-
5 Years-99.86%-99.97%-99.47%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Qualigen Therapeutics Inc with Peers
Ratio / StockQLGNMTPDRMAPXMD
PE-0.0830.847-1.99-0.052
P/B0.4381.162.650.535
ROA-156.96100.51-112.87-418.11
ROE-709.27137.12-132.91-1026.97
Debt To Equity-0.6180.0510-0.148
Revenue4983.56 K
0 % 		699000
20.93 % 		0
% 		0
%
Net Income-17339.21 K
17.57 % 		-7656.00 K
40.22 % 		-7330.32 K
23.73 % 		-17589.90 K
18.84 %


Technicals of Qualigen Therapeutics Inc with Peers
Technical / StockQLGNMTPDRMAPXMD-
ADX12.0150.2528.4823.38
CMF0.0383-0.294-0.0129-0.271
MFI38.5212.2766.075.75
RSI43.7620.2280.6334.51
MACD Abv SignalTrueTrueTrueFalse
Price Above 50 MAFalseFalseTrueFalse-
Price Above 200 MAFalseFalseTrueFalse-


About : Qualigen Therapeutics Inc

Address : 2042 Corte Del Nogal, Carlsbad, CA, United States, 92011
Tel : 760 918 9165
URL : https://www.qualigeninc.com
Code : QLGN, ISIN : US74754R1032, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 24_Jun_2015
Employee Count : 4

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.


Note : All Data Generated at the End of Trading Hours (EOD Data)